

**FINAL REPORT**  
**Volume 1 of 12**

**Guidelines: OECD (451) and JMHLW (Ordinance No. 21)**

**Testing Facility Study No. EBA00009**

**Sponsor Ref. No. P00012-04-11**

**A Two Year Oral (Gavage) Carcinogenicity Study in Rats with BG00012**

**TESTING FACILITY:**

Charles River Laboratories  
Preclinical Services  
640 North Elizabeth Street  
Spencerville, OH 45887

**SPONSOR:**

Biogen Idec Inc.  
14 Cambridge Center  
Cambridge, MA 02142



**February 28, 2008**

**Page 1 of 4817**

**1. COMPLIANCE STATEMENT**

This study was conducted in compliance with the Good Laboratory Practice (GLP) regulations as described by the FDA (21 CFR Part 58); the Organisation for Economic Cooperation and Development (OECD) Principles of Good Laboratory Practice, C(97)186; and the Japanese Ministry of Health, Labor, and Welfare (MHLW) Ordinance No. 21 with the following exception(s):

Characterization and stability analyses of the bulk test article were conducted in compliance with the Good Manufacturing Practice regulations. Toxicokinetic interpretation was not conducted in compliance with the GLP regulations.

	
_____	_____
Mark A. Morse, Ph.D., DABT	Date
Study Director	
Charles River Laboratories	
Preclinical Services	

## 2. QUALITY ASSURANCE STATEMENT

This study has been inspected by the Quality Assurance Unit to assure conformance with the Good Laboratory Practice (GLP) regulations promulgated by the FDA (21 CFR Part 58); OECD Principles of Good Laboratory Practice, C(97)186; and the Japanese MHLW Ordinance No. 21. Reports were submitted in accordance with Standard Operating Procedures as follows:

### QA INSPECTION DATES

Dates of Inspection	Phase(s) Inspected	Date Findings Submitted to:	
		Study Director	Study Director Management
10/12/04	Animal Receipt Procedure	10/12/04	10/12/04
10/12/04	Protocol Review	10/15/04	10/15/04
10/14/04	Animal Receipt	10/15/04	10/15/04
10/25/04	Animal Identification	10/28/04	10/28/04
10/25/04	Randomization Procedure	10/28/04	10/28/04
10/25/04	Dose Preparation	10/28/04	10/28/04
10/25/04	Analytical Sampling	10/28/04	10/28/04
10/25/04	Test Article Receipt Procedure	11/01/04	11/01/04
10/26/04	Body Weights	10/28/04	10/28/04
10/26/04	Detailed Clinical Observations	10/28/04	10/28/04
10/26/04	Food Consumption	10/28/04	10/28/04
10/26/04	Dosing	10/28/04	10/28/04
11/01/04	Retention Sample	11/01/04	11/01/04
11/04/04	Protocol Amendment Review	02/11/05	02/11/05
01/18/05, 02/16/05, 02/22/05, 09/02/05, 09/12/05, 09/19/05, 10/20/05	Data Audit	11/14/05	11/14/05
03/07/05	Dosing	03/08/05	03/08/05
03/07/05	Dose Preparation	03/08/05	03/08/05
03/07/05	Analytical Sampling	03/08/05	03/08/05
03/08/05	Detailed Clinical Observations	03/08/05	03/08/05
03/15/05	Body Weights	03/15/05	03/15/05
03/15/05	Food Consumption	03/15/05	03/15/05
03/15/05	Protocol Amendment Review	05/27/05	05/27/05
04/05/05	Toxicokinetic Blood Collection	04/05/05	04/05/05
04/05/05	Plasma Processing	04/05/05	04/05/05
04/05/05	Dosing	04/05/05	04/05/05
04/26/05	Protocol Amendment Review	05/27/05	05/27/05
05/23/05	Dose Preparation	05/23/05	05/23/05
05/23/05	Dosing	05/23/05	05/23/05
09/12/05	Dose Preparation	09/13/05	09/13/05
09/12/05	Dosing	09/13/05	09/13/05
09/13/05	Detailed Clinical Observations	09/13/05	09/13/05
09/13/05	Palpable Masses	09/13/05	09/13/05
10/03/05	Bioanalytical Sample Shipping	10/03/05	10/03/05
10/17/05	Protocol Amendment Review	10/17/05	10/17/05
12/29/05	Protocol Amendment Review	05/03/06	05/03/06

Dates of Inspection	Phase(s) Inspected	Date Findings Submitted to:	
		Study Director	Study Director Management
01/09/06	Dose Preparation	01/09/06	01/09/06
01/09/06	Dosing	01/09/06	01/09/06
01/09/06	Analytical Sampling	01/09/06	01/09/06
02/03/06	Data Audit	02/16/06	02/16/06
03/01/06, 03/02/06	Data Audit	03/02/06	03/02/06
03/13/06	Dose Preparation	03/14/06	03/14/06
03/14/06	Dosing	03/14/06	03/14/06
03/14/06	Food Consumption	03/14/06	03/14/06
04/07/06, 04/10/06, 04/11/06	Data Audit	04/11/06	04/11/06
04/19/06	Sentinel Blood Collection	04/19/06	04/19/06
04/19/06	Serum Processing	04/19/06	04/19/06
05/19/06	Protocol Amendment Review	05/26/06	05/26/06
05/25/06	Data Audit	05/25/06	05/25/06
06/19/06	Dose Preparation	06/19/06	06/19/06
06/19/06	Dosing	06/19/06	06/19/06
06/20/06	Protocol Amendment Review	07/07/06	07/07/06
06/26/06	Analytical Sampling	07/07/06	07/07/06
08/31/06	Data Audit	08/31/06	08/31/06
09/01/06, 09/06/06, 09/07/06, 09/08/06, 09/18/06, 09/19/06	Data Audit	09/19/06	09/19/06
09/07/06	Data Audit	09/07/06	09/07/06
09/08/06	Data Audit	09/08/06	09/08/06
09/11/06	Dose Preparation	09/12/06	09/12/06
09/11/06	Dosing	09/12/06	09/12/06
09/12/06	Detailed Clinical Observations	09/12/06	09/12/06
09/12/06	Palpable Masses	09/12/06	09/12/06
09/14/06	Data Audit	09/15/06	09/15/06
09/18/06	Data Audit	09/18/06	09/18/06
09/19/06, 09/20/06	Data Audit	09/21/06	09/21/06
10/23/06	Protocol Amendment Review	10/23/06	10/23/06
10/24/06	Necropsy	10/27/06	10/27/06
10/25/06	Clinical Pathology Blood Collection	10/27/06	10/27/06
10/26/06	Data Audit	10/27/06	10/27/06
10/27/06	Sentinel Blood Collection	10/27/06	10/27/06
10/27/06	Serum Processing	10/27/06	10/27/06
10/31/06	Data Audit	10/31/06	10/31/06
11/01/06	Data Audit	11/01/06	11/01/06
11/03/06	Data Audit	11/03/06	11/03/06
11/06/06	Data Audit	11/06/06	11/06/06
11/08/06	Protocol Amendment Review	11/15/06	11/15/06
11/15/06, 11/16/06	Data Audit	11/16/06	11/16/06
11/22/06	Trimming	11/28/06	11/28/06
11/27/06, 11/28/06, 11/29/06	Data Audit	11/29/06	11/29/06
11/30/06	Data Audit	11/30/06	11/30/06
12/04/06, 12/05/06	Data Audit	12/05/06	12/05/06

Dates of Inspection	Phase(s) Inspected	Date Findings Submitted to:	
		Study Director	Study Director Management
12/05/06	Data Audit	12/08/06	12/08/06
12/06/06, 12/07/06	Data Audit	12/11/06	12/11/06
12/07/06, 12/08/06, 12/11/06	Data Audit	12/12/06	12/12/06
12/21/06	Data Audit	12/21/06	12/21/06
01/09/07	Protocol Amendment Review	01/11/07	01/11/07
01/11/07	Microtomy	01/12/07	01/12/07
01/26/07	Quality Control	01/29/07	01/29/07
04/21/07	Protocol Amendment Review	05/01/07	05/01/07
06/19/07	Protocol Amendment Review	06/19/07	06/19/07
07/06/07, 07/10/07, 07/11/07, 07/12/07, 07/16/07, 07/17/07, 07/18/07, 07/19/07	Draft Report Review	07/20/07	07/20/07
10/16/07	Protocol Amendment Review	10/29/07	10/29/07
01/28/08	Protocol Amendment Review	01/31/08	01/31/08
02/19/08, 02/20/08	Final Report Review	02/20/08	02/20/08

QA statement(s) provided by the following test site(s) have been reviewed:

Test Site(s)	Phase	QA Statement Location
Charles River Laboratories, Preclinical Services	Analytical Chemistry Report	<a href="#">Appendix 3</a>
Charles River Laboratories	Pretest Health Screen (Serology)	<a href="#">Appendix 4</a>
Charles River Laboratories	Sentinel Animals (Serology)	<a href="#">Appendix 5</a>
Charles River Laboratories, Pathology Associates	Histopathology Report	<a href="#">Appendix 13</a>
Charles River Laboratories, Pathology Associates	Histopathology Peer Review	<a href="#">Appendix 13</a>
BioSTAT Consultants, Inc.	Statistical Analysis of Survival and Tumor Incidence	<a href="#">Appendix 14</a>
Charles River Laboratories, Preclinical Services	Bioanalytical Report	<a href="#">Appendix 18</a>
Biogen Idec Inc.	Toxicokinetic Interpretive Report	<a href="#">Appendix 19</a>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.